Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dupilumab in Moderate to Severe Asthma
NCT04743791Phase 4Recruiting
- Start
- Oct 2022
- Primary completion
- Dec 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in asthma comparing Dupilumab with Placebo (2 arms). Primary endpoint: Mucociliary clearance rate at 12 weeks. Started Oct 2022; status: recruiting.
02
Drugs
03
Conditions
asthma
Beyond the preview
Go deeper on NCT04743791.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04743791.